Search results
Showing 46 to 60 of 104 results for psychosis
Recommendation ID CG120/3 Question Is providing treatment for psychosis and substance misuse services within staffed accommodation more...
clinical and cost effectiveness of peer support interventions in people with psychosis and schizophrenia? Any explanatory notes(if...
of guided medication discontinuation and/or reduction in first episode psychosis and can this be achieved without major risks? Any...
rehabilitation services compared with treatment as usual for people with complex psychosis with residual disability, who are leaving...
protective factors, and course of illness for different combinations of psychosis and coexisting substance misuse (for example,...
of ADHD medications in people with ADHD and tic disorders, a history of psychosis or mania, or personality disorder? Any explanatory...
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
Learning disability: identifying and managing mental health problems (QS142)
This quality standard covers the prevention, assessment and management of mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It also covers family members, carers and care workers.
View quality statements for QS142Show all sections
Sections for QS142
- Quality statements
- Quality statement 1: Annual health check
- Quality statement 2: Assessment by a professional with relevant expertise
- Quality statement 3: Key worker
- Quality statement 4: Tailoring psychological interventions
- Quality statement 5: Annually documenting the reasons for continuing antipsychotic drugs
- Update information
- About this quality standard
This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186
Autism spectrum disorder in under 19s: recognition, referral and diagnosis (CG128)
This guideline covers recognising and diagnosing autism spectrum disorder in children and young people from birth up to 19 years. It also covers referral. It aims to improve the experience of children, young people and those who care for them.
This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing information and support, and palliative care.
learning disabilities, people with personality disorder, people with complex psychosis, people with long-term severe mental illness and...
important:- Rivastigmine is commonly used to treat Parkinson's disease psychosis because it has shown some effectiveness in improving...
This guideline covers using psychosocial interventions to treat adults and young people over 16 who have a problem with or are dependent on opioids, stimulants or cannabis. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.
major sources of morbidity and premature mortality in young people with psychosis and schizophrenia. Most evidence of adverse effects...